Search Result

Results for "

metabolism disorders

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (1) Biochemical Assay Reagents (2) Btk (1) Cytochrome P450 (1) Drug Metabolite (1) Endogenous Metabolite (7) FABP (2) Ferroportin (1) Fungal (3) FXR (1) Isotope-Labeled Compounds (1) mAChR (1) mTOR (1) Parasite (1) Phosphodiesterase (PDE) (1) PPAR (1) RAR/RXR (1) ROR (1) Sirtuin (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (7) Infection (4) Inflammation/Immunology (2) Metabolic Disease (12) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Mitochondrial Metabolism

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136584

2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid	Others	Cardiovascular Disease Metabolic Disease
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders .

HY-B1134

Imazalil 1 Publications Verification Enilconazole	Fungal	Infection
Imazalil (Enilconazole) is a fungicide. Imazalil has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil is commonly used to protect various agricultural crops against fungal attack. Imazalil induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .

HY-160548

mTOR inhibitor-18	mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders .

HY-147379

Hepcidin antagonist-1	Others	Metabolic Disease
Hepcidin antagonist-1 (example 104) is a potent hepcidin (hepcidine) antagonist with an IC₅₀<50 μM. Hepcidin antagonist-1 can be used for researching iron metabolism disorders, such as anemias .

HY-B1134A

Imazalil sulfate Enilconazolel sulfate	Fungal	Infection
Imazalil (Enilconazole) sulfate is a fungicide. Imazalil sulfate has oral activity and strongly activates mPXR but not mCAR in mouse liver. Imazalil sulfate is commonly used to protect various agricultural crops against fungal attack. Imazalil sulfate induces developmental abnormalities, gut microbiota dysbiosis, and hepatic metabolism disorder .

HY-18078

PQ-10	Phosphodiesterase (PDE)	Neurological Disease
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC₅₀ andED₅₀ of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .

HY-113121

Vanillylmandelic acid 2 Publications Verification	Endogenous Metabolite	Cardiovascular Disease
Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC₅₀ value of 33 μM .

HY-113121S1

Vanillylmandelic acid-d1	Isotope-Labeled Compounds Endogenous Metabolite	Cardiovascular Disease
Vanillylmandelic acid-d is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM[1].

HY-113121S

Vanillylmandelic acid-d3	Endogenous Metabolite	Cardiovascular Disease
Vanillylmandelic acid-d₃ is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM[1].

HY-113121R

Vanillylmandelic acid (Standard)	Drug Metabolite Endogenous Metabolite	Cardiovascular Disease
Vanillylmandelic acid (Standard) is the analytical standard of Vanillylmandelic acid. This product is intended for research and analytical applications. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC₅₀ value of 33 μM .

HY-E70239

2-Methylbutyryl-CoA	Others	Others
2-Methylbutyryl-CoA is an intermediate of isoleucine metabolism. 2-Methylbutyryl-CoA dehydrogenase deficiency is a genetic disorder caused by mutations in the HADH2 gene .

HY-113013

Hydroxypyruvic acid β-Hydroxypyruvic acid; 3-Hydroxypyruvic acid	Endogenous Metabolite	Metabolic Disease
Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Cardiovascular Disease Metabolic Disease
Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases .

HY-145965

Ferroportin-IN-1	Ferroportin	Metabolic Disease
Ferroportin-IN-1 is a ferroportin inhibitor extracted from patent WO2020123850A1 compound 23. Ferroportin-IN-1 can be used for the research of diseases caused by a lack of hepcidin or iron metabolism disorders .

HY-142932

BTK-IN-6	Btk	Neurological Disease Inflammation/Immunology Cancer
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .

HY-156354

GPR61 Inverse agonist 1	Others	Metabolic Disease
GPR61 Inverse agonist 1 (Compound 1) is a GPR61 inverse agonist (IC₅₀: 11 nM). GPR61 Inverse agonist 1 can be used for research of disorders of metabolism and body weight, such as obesity and cachexia .

HY-101036

Choline bitartrate 2 Publications Verification	mAChR Endogenous Metabolite	Neurological Disease Cancer
Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders . Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism .

HY-113013A

Hydroxypyruvic acid lithium hydrate β-Hydroxypyruvic acid lithium hydrate; 3-Hydroxypyruvic acid lithium hydrate	Endogenous Metabolite	Metabolic Disease
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.

HY-W004563

Neocuproine	Biochemical Assay Reagents	Others
Neocuproine is an organic compound commonly used as a complexing reagent and copper ion detector. It can form stable complexes with copper ions, and can play a catalytic role in certain chemical reactions and analytical methods. In addition, this compound is also widely used in some biomedical fields, such as in the study of copper metabolism disorders and neurodegenerative diseases

HY-160456

FABP4/5-IN-4	FABP	Metabolic Disease
FABP4/5-IN-4 (compound E1) is a potent inhibitor of FABP4 and FABP5, with the IC₅₀s of 3.78 μM and 5.72 μM, respectively. FABP4/5-IN-4 plays an important role in metabolism disorder like diabetes mellitus .

HY-160457

FABP4/5-IN-5	FABP	Metabolic Disease
FABP4/5-IN-5 (compound D9) is a potent inhibitor of FABP4 and FABP5,? with the IC₅₀s of 4.68 μM and 10.72 μM, respectively.FABP4/5-IN-5 plays an important role in metabolism disorder like diabetes mellitus .

HY-156328

NSC 48160	Apoptosis	Cancer
NSC 48160 inhibits the growth of the pancreatic cancer cells with IC₅₀s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .

HY-W127805

Pentacarboxylporphyrin I dihydrochloride	Biochemical Assay Reagents	Others
Pentacarboxylporphyrin I dihydrochloride is an organic compound belonging to the family of porphyrin derivatives. It is commonly used in biochemical research as a reference standard for the quantification of porphyrins and related compounds in biological samples. Pentacarboxylporphyrin I dihydrochloride has several applications in the diagnosis and monitoring of porphyrias, a group of inherited disorders characterized by abnormalities in heme metabolism. In addition, it can be used as a photosensitizer in photodynamic therapy for the improvement of cancer and other diseases.

HY-117006

E1231 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-13582

Carbendazim 4 Publications Verification	Fungal Parasite	Infection Cancer
Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	2,361 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2,361 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2,361 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,361 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L009

Kinase Inhibitor Library	2,673 compounds
Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. Kinase inhibitor library designed by MCE contains 2,673 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Kinase Inhibitor Library

2,673 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 2,673 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Neocuproine	Biochemical Assay Reagents
Neocuproine is an organic compound commonly used as a complexing reagent and copper ion detector. It can form stable complexes with copper ions, and can play a catalytic role in certain chemical reactions and analytical methods. In addition, this compound is also widely used in some biomedical fields, such as in the study of copper metabolism disorders and neurodegenerative diseases

Pentacarboxylporphyrin I dihydrochloride	Biochemical Assay Reagents
Pentacarboxylporphyrin I dihydrochloride is an organic compound belonging to the family of porphyrin derivatives. It is commonly used in biochemical research as a reference standard for the quantification of porphyrins and related compounds in biological samples. Pentacarboxylporphyrin I dihydrochloride has several applications in the diagnosis and monitoring of porphyrias, a group of inherited disorders characterized by abnormalities in heme metabolism. In addition, it can be used as a photosensitizer in photodynamic therapy for the improvement of cancer and other diseases.

(Z)-KC02	Drug Delivery
(Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo .

Prafnosbart DS-6016A	Inhibitory Antibodies	Metabolic Disease
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .

Cat. No.	Product Name	Category	Target	Chemical Structure